Previous studies have suggested that the medical nutriment MSC has antimetastatic activity and no toxicity.
In this open-label cohort trial, researchers from Hungary and Israel evaluated this in colorectal cancer patients. They compared anticancer treatments plus MSC (9g daily) with anticancer treatments alone.
There were 170 patients were enrolled from 3 oncosurgical centers.
Of these patients, 66 received MSC supplementation for more than 6 months, while 104 controls received anticancer drugs only.
|New recurrences occurred in 3% of patients in the MSC group, compared with 17% of controls.|
|British Journal of Cancer|
Using end-point analysis, the investigators found that progression-related events were significantly less frequent in the patients who received MSC supplementation.
They determined that new recurrences occurred in 3% of patients in the MSC group, compared with 17% of controls. In addition, new metastases occurred in 8% of the MSC group and 23% of controls, and death occurred in 12% versus 32%.
Furthermore, survival analysis identified a significant improvement in progression-free survival in the MSC group, as well as in overall survival.
The team found that UICC stage and MSC treatment were independent predictors of survival.
Dr Jakab's team concluded, "Continuous supplementation of anticancer therapies with MSC for more than 6 months is beneficial to patients with colorectal cancer in terms of overall and progression-free survival".